News & Media

/News & Media
News & Media 2018-04-16T20:35:19+00:00

Press Release

20 November 2017

Swiss biotech company TargImmune is announcing a new international research collaboration with Australia’s oldest medical research institute, the Walter and Eliza Hall Institute, to progress the development of a cutting-edge cancer immunotherapy platform. Building on the expertise of Professor Alexander Levitzki’s 15-year development of this technology, leading Walter and Eliza Hall Institute cancer researcher Professor Tony Burgess will use TargImmune’s novel drug platform for pre-clinical research at WEHI. TargImmune CEO Dr Esteban Pombo-Villar said the company’s proprietary technology…

Full article

10 July 2017

Race Oncology Limited (ASX: RAC) announced today that it has executed a Letter of Intent with TargImmune Therapeutics AG (Basel, Switzerland) to enter into a joint venture between the two companies. The joint venture, to be called Race Immunotherapeutics, will focus on developing new and improved cancer therapies based on combining Bisantrene with TargImmune’s targeted cancer therapy technology. The Race Immunotherapeutics (“RITX”) joint venture will be a 50:50 partnership between Race and TargImmune, and all new intellectual property created by RITX…

Full article

Targimmune in the News

23 November 2017

Australian researchers have been called in to join an international effort to fight cancer using a new technique that boosts the body’s immune system. Known as immunotherapy, the treatment seeks to target individual cancer cells while also boosting the patient’s immune system so cancerous tissues are destroyed whilst leaving healthy areas untouched. This is in contrast to more usual cancer treatments like radiation or chemotherapy that take a blanket approach, targeting the cancerous cells in a way that also affects normal tissues.

Full article

23 November 2017

Swiss biotech company TargImmune is announcing a new international research collaboration with Australia’s oldest medical research institute, the Walter and Eliza Hall Institute, to progress the development of a cutting-edge cancer immunotherapy platform. Building on the expertise of Professor Alexander Levitzki’s 15-year development of this technology, leading Walter and Eliza Hall Institute cancer researcher Professor Tony Burgess will use TargImmune’s novel drug platform for pre-clinical research at WEHI. TargImmune CEO Dr Esteban Pombo-Villar said the company’s proprietary technology…

Full article

21 November 2017

Perth researchers have been called in to join an international effort to fight cancer using a new technique that boosts the body’s immune system. Known as immunotherapy, the treatment seeks to target individual cancer cells while also boosting the patient’s immune system so cancerous tissues are destroyed whilst leaving healthy areas untouched. This is in contrast to more usual cancer treatments like radiation or chemotherapy that take a blanket approach, targeting the cancerous cells in a way that also affects normal tissues. The treatment is being advanced by Swiss biotech company TargImmune…

Full article

21 November 2017

Australian researchers have been called in to join an international effort to fight cancer using a new technique that boosts the body’s immune system. Known as immunotherapy, the treatment seeks to target individual cancer cells while also boosting the patient’s immune system so cancerous tissues are destroyed whilst leaving healthy areas untouched. This is in contrast to more usual cancer treatments like radiation or chemotherapy that take a blanket approach, targeting the cancerous cells in a way that also affects normal tissues.

Full article

21 November 2017

The Melbourne-based Walter and Eliza Hall Institute has signed a new international research collaboration with Swiss biotech company TargImmune focussed on progressing development of a cutting-edge cancer immunotherapy platform. As part of the collaboration, Walter and Eliza Hall Institute cancer researcher Professor Tony Burgess will use TargImmune’s novel drug platform for pre-clinical research at WEHI. TargImmune Therapeutics AG was established in March 2016. According to TargImmune CEO, Dr Esteban Pombo-Villar, the company’s technology platform involves a personalised approach…

Full article

11 July 2017

The Basel-based company TargImmune Therapeutics AG and the Australian Race Oncology Limited are entering into a joint venture to develop new cancer therapies. The R&D work will be done in Basel. TargImmune Therapeutics and Race Oncology announced that they have executed a letter of intent to establish a joint venture called Race Immunotherapeutics (RITX). The joint venture, which will be equally co-owned by both parties, will focus on developing new cancer therapies. RITX will develop the new therapies based on a TargImmune technology that was in-licensed from the Hebrew University…

Full article

10 July 2017

Australian-based specialist pharmaceutical firm Race Oncology has executed a Letter of Intent (LoI) with Swiss-based biotechnology TargImmune Therapeutics to enter a joint venture (JV) between the two companies to develop new and improved cancer therapies. The new 50:50 JV is to be called Race Immunotherapeutics (RITX) and will focus on developing these therapies based on combining Race’s chemotherapy drug, Bisantrene, with TargImmune’s targeted cancer therapy technology. The new intellectual property created by RITX will be equally co-owned by both parties…

Full article